Related Experiment Video
Updated: Aug 6, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Biosimilars: how similar or dissimilar are they?
1Renal Unit, Gosford Hospital, Gosford, New South Wales, Australia. sroger@nsccahs.health.nsw.gov.au
Nephrology (Carlton, Vic.)
|August 8, 2006
Summary
Biosimilars, or similar biological medicinal products, differ significantly from generic chemical drugs due to their complexity. Regulatory agencies are developing approaches for biosimilar approval, emphasizing safety and efficacy through extensive clinical trials.
Area of Science:
- Biopharmaceutical science
- Nephrology
- Regulatory science
Background:
- Patent expiry of biological medicines like epoetin alfa necessitates understanding biosimilars.
- Biosimilars are similar biological medicinal products, distinct from generic chemical drugs.
Purpose of the Study:
- To review differences between biosimilars and generic low molecular weight drugs.
- To discuss regulatory approaches to biosimilars by agencies like EMEA and TGA.
- To highlight safety and efficacy considerations for biosimilars in nephrology.
Main Methods:
- Comparative analysis of biosimilar and generic drug characteristics.
- Review of regulatory agency guidelines and principles.
- Discussion of clinical trial requirements for biosimilar approval.
Main Results:
- Biosimilars are larger, more complex molecules than generic chemical drugs.
- Manufacturing processes for biosimilars are more intricate.
- Established 'essential similarity' principles for generics are not directly applicable to biosimilars.
- Extensive clinical trials are required to demonstrate biosimilar safety and efficacy.
Conclusions:
- Biosimilars present unique challenges compared to generic drugs.
- Regulatory frameworks must adapt to the complexity of biosimilars.
- Ensuring the safety and efficacy of biosimilars through rigorous testing is paramount for clinical adoption in nephrology.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:17Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...